瑞迈特(301367) - 2026年2月26日投资者关系活动记录表

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The first CPAP sleep respirator was released in 2007, and the company received CE certification in 2008 and FDA certification in 2012. It successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2]. - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management. It is a leading domestic enterprise in home non-invasive ventilators and has obtained multiple certifications including NMPA, FDA, CE, and others, exporting to over 140 countries and regions [2][3]. Research and Development - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas authorized patents, including 45 in the U.S. and 38 in Europe [3]. Market Position - According to data from Sullivan in August 2024, the company holds a 12.4% market share in the global home non-invasive ventilator market, ranking second, while its domestic market share is 30.6%, making it the top domestic brand [4]. - The company aims to enhance brand building, optimize channel management, and strengthen cooperation with agents to further increase market share [4]. Strategic Investments - The company has invested in Shenzhen Deda Xing Drive Technology Co., Ltd., a leading provider of precision motors and solutions, to ensure the stability of core component supplies and promote business expansion into upstream industries [5]. - This investment aligns with the company's long-term strategic direction and enhances its core competitiveness [5]. Supply Chain Localization - The company has achieved significant progress in localizing its supply chain, with core component domestic replacement nearly complete, ensuring supply chain security and cost advantages [5]. - Future efforts will focus on optimizing domestic industrial chain collaboration to enhance business stability and risk resistance [5].